Page 38 - TD-4-3

Tumor Discovery Immunomodulatory effects of CDK4/6 inhibitors

positive breast cancer. Histopathology. 2024;87:3-17. 80. Wu S, Xu J, Ma Y, Liang G, Wang J, Sun T. Advances
in the mechanism of CDK4/6 inhibitor resistance
doi: 10.1111/his.15395
in HR+/HER2- breast cancer. Ther Adv Med Oncol.
72. Finn RS, Boer K, Bondarenko I, et al. Overall survival 2024;16:17588359241282499.
results from the randomized phase 2 study of palbociclib
in combination with letrozole versus letrozole alone doi: 10.1177/17588359241282499
for first-line treatment of ER+/HER2- advanced breast 81. Morrison L, Loibl S, Turner NC. The CDK4/6 inhibitor
cancer (PALOMA-1, TRIO-18). Breast Cancer Res Treat. revolution - a game-changing era for breast cancer treatment.
2020;183(2):419-428. Nat Rev Clin Oncol. 2024;21(2):89-105.
doi: 10.1007/s10549-020-05755-7 doi: 10.1038/s41571-023-00840-4
73. Im SA, Mukai H, Park IH, et al. Palbociclib plus letrozole 82. Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A.
as first-line therapy in postmenopausal Asian women CDK4/6 inhibitors: The mechanism of action may not be as
with metastatic breast cancer: Results from the phase III, simple as once thought. Cancer Cell. 2018;34(1):9-20.
randomized PALOMA-2 study. J Glob Oncol. 2019;5:1-19.
doi: 10.1016/j.ccell.2018.03.023
doi: 10.1200/JGO.18.00173
83. Teh JLF, Aplin AE. Arrested developments: CDK4/6
74. Cristofanilli M, Rugo HS, Im SA, et al. Overall survival Inhibitor resistance and alterations in the tumor immune
with palbociclib and fulvestrant in women with HR+/ microenvironment. Clin Cancer Res. 2019;25(3):921-927.
HER2- ABC: Updated exploratory analyses of PALOMA-3, doi: 10.1158/1078-0432.CCR-18-1967
a double-blind, phase III randomized study. Clin Cancer Res.
2022;28(16):3433-3442. 84. De Angelis C, Fu X, Cataldo ML, et al. Activation of the IFN
signaling pathway is associated with resistance to CDK4/6
doi: 10.1158/1078-0432.CCR-22-0305
inhibitors and immune checkpoint activation in ER-positive
75. Jhaveri K, O’Shaughnessy J, Fasching PA, et al. Matching- breast cancer. Clin Cancer Res. 2021;27(17):4870-4882.
adjusted indirect comparison of PFS and OS comparing doi: 10.1158/1078-0432.CCR-19-4191
ribociclib plus letrozole versus palbociclib plus letrozole as
first-line treatment of HR+/HER2- advanced breast cancer. 85. Sammons S, Moore H, Cushman J, Hamilton E. Efficacy,
Ther Adv Med Oncol. 2023;15:103580. safety and toxicity management of adjuvant abemaciclib in
early stage HR+/HER2- high-risk breast cancer. Expert Rev
doi: 10.1177/17588359231216095
Anticancer Ther. 2022;22(8):805-814.
76. Slamon DJ, Neven P, Chia S, et al. Phase III randomized doi: 10.1080/14737140.2022.2093719
study of ribociclib and fulvestrant in hormone receptor-
positive, human epidermal growth factor receptor 86. Nabieva N, Fasching PA. CDK4/6 inhibitors-overcoming
2-negative advanced breast cancer: MONALEESA-3. J Clin endocrine resistance is the standard in patients with
Oncol. 2018;36(24):2465-2472. hormone receptor-positive breast cancer. Cancers(Basel).
2023;15(6):1763.
doi: 10.1200/JCO.2018.78.9909
doi: 10.3390/cancers15061763
77. Lu YS, Im SA, Colleoni M, et al. Updated overall survival
of ribociclib plus endocrine therapy versus endocrine 87. Zhao S, Zhang H, Yang N, Yang J. A narrative review about
therapy alone in pre- and perimenopausal patients with CDK4/6 inhibitors in the setting of drug resistance: Updates
HR+/HER2- advanced breast cancer in MONALEESA-7: on biomarkers and therapeutic strategies in breast cancer.
A phase III randomized clinical trial. Clin Cancer Res. Transl Cancer Res. 2023;12(6):1617-1634.
2022;28(5):851-859. doi: 10.21037/tcr-22-2807
doi: 10.1158/1078-0432.CCR-21-3032
88. Dall’Acqua A, Bartoletti M, Masoudi-Khoram N, et al.
78. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final Inhibition of CDK4/6 as therapeutic approach for ovarian
PFS: A randomized study of abemaciclib as initial therapy cancer patients: Current evidences and future perspectives.
for advanced breast cancer. NPJ Breast Cancer. 2019;5:5. Cancers (Basel). 2021;13(12):3035.
doi: 10.1038/s41523-018-0097-z doi: 10.3390/cancers13123035
79. Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: 89. Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE.
Abemaciclib in combination with fulvestrant in women Immunomodulatory effects of BRAF, MEK, and CDK4/6
with HR+/HER2- advanced breast cancer who had inhibitors: Implications for combining targeted therapy
progressed while receiving endocrine therapy. J Clin Oncol. and immune checkpoint blockade for the treatment of
2017;35(25):2875-2884. melanoma. Front Immunol. 2021;12:661737.
doi: 10.1200/JCO.2017.73.7585 doi: 10.3389/fimmu.2021.661737

Volume 4 Issue 3 (2025) 30 doi: 10.36922/TD025190037